Resilience

Resilience, established in 2020 and headquartered in La Jolla, California, is a biopharmaceutical manufacturing and technology company. It specializes in providing end-to-end manufacturing and development solutions for complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. Resilience invests in developing new manufacturing technologies to ensure rapid, safe, and scalable production, thereby enhancing patient access to these treatments. The company partners with biopharmaceutical companies to focus on breakthrough discoveries while Resilience manages the manufacturing process, safeguarding supply chains against future disruptions.

Rahul Singhvi

Co-Founder and CEO

6 past transactions

PartnerSlate

Seed Round in 2023
PartnerSlate is an online platform designed to facilitate strategic partnerships between food and beverage brands and manufacturing and packaging partners across North America. The platform enables brands to discover and connect with contract manufacturers by streamlining the manufacturing process through various criteria, such as location, capabilities, and product categories. This approach helps brands identify suitable production companies that align with their needs, ultimately supporting them in bringing their products to market efficiently. PartnerSlate serves as a valuable resource for the food industry, fostering relationships that enhance collaboration and drive business growth.

Swiftscale Biologics

Acquisition in 2021
Swiftscale Biologics is a healthcare service provider based in South San Francisco, California, founded in 2019. The company specializes in cell-free protein synthesis, focusing on rapid expression, high-throughput synthesis, and the production of complex proteins. Its innovative platform is designed to test and develop antibodies that inhibit the interaction between viral proteins and human host cells, effectively stopping ongoing coronavirus infections. By advancing these life-saving drugs, Swiftscale Biologics aims to enhance patient outcomes and improve overall health.

Cellevolve Bio

Seed Round in 2021
Cellevolve Bio is a development and commercialization company specializing in cell therapies aimed at neglected diseases. The company collaborates with innovators to transition early-stage clinical therapies into commercially available treatments, particularly for pediatric and rare diseases. By advancing these therapies into clinical development, Cellevolve aims to significantly enhance patient outcomes and provide expertise in cell therapy and clinical care.

bit.bio

Series B in 2021
Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.

Garuda Therapeutics

Series A in 2021
Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.

Ology Bioservices

Acquisition in 2021
Ology Bioservices is an integrated biopharmaceutical company specializing in the development and manufacturing of biopharmaceutical products and medical devices. Founded in 1999 and restructured in 2017, the company operates as a contract development and manufacturing organization (CDMO), providing services that include preclinical and clinical development, formulation optimization, and cGMP manufacturing. Ology Bioservices supports a wide range of drug types, from small molecules to proteins and vaccines, enabling clients to access high-quality biopharmaceutical solutions efficiently and cost-effectively. The company is equipped to manufacture products in compliance with BSL-3 standards, ensuring that it can cater to various client needs within the biopharmaceutical sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.